In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

There were reimbursement woes and social media shifts, plus good news for the dual GIP/GLP-1 drug tirzepatide (Zepbound ... Sex Differences Seen for FFR-Guided PCI vs CABG in FAME 3 The optimal ...

The only difference between the two is that the FDA has approved Zepbound for weight loss and Mounjaro for type 2 diabetes. These prescription medications are part of the same class of drugs as ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

One stark difference between years is the growing ... 2024 tracker are Ozempic- and Wegovy-seller Novo Nordisk, and Zepbound- and Mounjaro-maker Eli Lilly after the obesity market exploded in ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Childhood obesity between 1975 and 2022 has increased ... Eli Lilly markets tirzepatide through two brand names: Mounjaro and Zepbound. The former has been approved by the FDA to combat type ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...